Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani.
Fusarium spp. have emerged as important causes of invasive fungal infections in immunocompromised patients. Rabbit pulmonary alveolar macrophages (PAMs) exhibited fungicidal activity against conidia of Fusarium solani and achieved a time-dependent increase in killing. Neither deoxycholate amphotericin B (DAMB) nor amphotericin B lipid complex (ABLC) exerted a suppressive effect on PAMs by decreasing their conidiocidal activity against F. solani. On the contrary, at a concentration of 0.125 microg ml(-1), ABLC and, to a lesser degree, DAMB additively augmented the fungicidal activity of pulmonary alveolar macrophages against conidia of Fusarium solani.
Roilides
Emmanuel
E
Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MA, USA.
Lyman
Caron A
CA
Armstrong
Derek
D
Stergiopoulou
Theodouli
T
Petraitiene
Ruta
R
Walsh
Thomas J
TJ
D000666:Amphotericin B / Q000494:pharmacology*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003840:Deoxycholic Acid / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D005670:Fusarium / Q000187:drug effects* / Q000276:immunology*; D006801:Humans; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000276:immunology*; D010713:Phosphatidylcholines / Q000494:pharmacology*; D010715:Phosphatidylglycerols / Q000494:pharmacology*; D011817:Rabbits
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination